Company intelligence / Profile preview

China Spring Fund

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Springhill Fund (泉创资本) is a leading healthcare-focused venture capital firm based in China, with offices in Shanghai and Hong Kong. The firm specializes in early to growth-stage investments across the healthcare spectrum, including biotechnology, pharmaceuticals, medical devices, and healthcare services. Springhill Fund is recognized for its deep industry expertise and its role in supporting prominent Chinese biotech companies such as Zai Lab, New Horizon Health, and Antengene. The firm aims to bridge global innovation with the Chinese healthcare market through strategic investments and operational support, often participating in significant financing rounds for high-growth life science entities.

Industry: Investors

Beyond the preview

Go deeper on China Spring Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Spring Fund.

Explore the full profile